Glen Eagle Advisors LLC Raises Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Glen Eagle Advisors LLC boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6,753.3% in the first quarter, Holdings Channel.com reports. The firm owned 2,056 shares of the company’s stock after buying an additional 2,026 shares during the quarter. Glen Eagle Advisors LLC’s holdings in IDEXX Laboratories were worth $1,155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $26,000. SHP Wealth Management purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $26,000. WealthCollab LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories during the third quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $556.20 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $43.87 billion, a price-to-earnings ratio of 40.96, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The company’s 50-day moving average is $556.48 and its 200 day moving average is $593.74.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm posted $2.91 earnings per share. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. UBS Group decreased their target price on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating for the company in a research note on Monday. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $749.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.